Bernardini Francesco P, Gennai Alessandro, Izzo Luigi, Zambelli Alessandra, Repaci Erica, Baldelli Ilaria, Fraternali-Orcioni G, Hartstein Morris E, Santi Pier Luigi, Quarto Rodolfo
Drs Bernardini and Zambelli are oculofacial plastic surgeons in private practice in Genova, Milano, and Torino, Italy. Drs Gennai and Izzo are plastic surgeons in private practice in Bologna, Italy. Dr Repaci and Prof Dr Quarto are Researchers in the Department of Experimental Medicine, University of Genova, Italy. Dr Baldelli and Prof Dr Santi are Plastic Surgeons in the Department of Integrated Surgical and Diagnostic Sciences, University of Genova, Italy. Dr Fraternali-Orcioni is a Pathologist in the Department of Pathology, University of Genova, Italy. Dr Hartstein is an Oculofacial Plastic Surgeon at Assaf Harofhe Medical Center in Zerifin, Israel.
Aesthet Surg J. 2015 Jul;35(5):504-15. doi: 10.1093/asj/sjv001. Epub 2015 Apr 24.
Although recent research on micro fat has shown the potential advantages of superficial implantation and high stem cell content, clinical applications thus far have been limited.
The authors report their experience with superficial enhanced fluid fat injection (SEFFI) for the correction of volume loss and skin aging of the face in general and in the periocular region.
The finer SEFFI preparation (0.5 mL) was injected into the orbicularis in the periorbital and perioral areas, and the 0.8-mL preparation was injected subdermally elsewhere in the face.
The records of 98 consecutive patients were reviewed. Average follow-up time was 6 months, and average volume of implanted fat was 20 mL and 51.4 mL for the 0.5-mL and 0.8-mL preparations, respectively. Good or excellent results were achieved for volume restoration and skin improvement in all patients. Complications were minor and included an oil cyst in 3 patients. The smaller SEFFI quantity (0.5 mL) was well suited to correct volume loss in the eyelids, especially the deep upper sulcus and tear trough, whereas the larger SEFFI content was effective for larger volume deficits in other areas of the face, including the brow, temporal fossa, zygomatic-malar region, nasolabial folds, marionette lines, chin, and lips.
The fat administered by SEFFI is easily harvested via small side-port cannulae, yielding micro fat that is rich in viable adipocytes and stem cells. Both volumes of fat (0.5 mL and 0.8 mL) were effective for treating age-related lipoatrophy, reducing facial rhytids, and improving skin quality.
4 Therapeutic.
尽管最近关于微脂肪的研究显示了其浅层植入和高干细胞含量的潜在优势，但迄今为止其临床应用仍然有限。
作者报告了他们使用浅层强化脂肪注射液（SEFFI）矫正面部尤其是眼周区域容量缺失和皮肤老化的经验。
将更精细的SEFFI制剂（0.5毫升）注射到眶周和口周区域的眼轮匝肌中，0.8毫升制剂则注射到面部其他部位的皮下。
回顾了98例连续患者的记录。平均随访时间为6个月，0.5毫升和0.8毫升制剂植入脂肪的平均量分别为20毫升和51.4毫升。所有患者在容量恢复和皮肤改善方面均取得了良好或优异的效果。并发症轻微，包括3例患者出现油囊肿。较小剂量的SEFFI（0.5毫升）非常适合矫正眼睑的容量缺失，尤其是上睑深沟和泪沟，而较大剂量的SEFFI对面部其他区域的较大容量缺损有效，包括眉部、颞窝、颧颊区域、鼻唇沟、木偶纹、下巴和嘴唇。
通过SEFFI注入的脂肪易于通过小侧孔套管采集，产生富含活脂肪细胞和干细胞的微脂肪。两种剂量的脂肪（0.5毫升和0.8毫升）在治疗与年龄相关的脂肪萎缩、减少面部皱纹和改善皮肤质量方面均有效。
4 治疗性。
